ARMP Armata Pharmaceuticals, Inc.
Debt Financing ·
The 14.0% term loan matures in January 2029 and is secured by substantially all of the company's assets. The lender is a subsidiary of Innoviva, which the filing describes as a principal shareholder.
The term loan from Innoviva Strategic Opportunities LLC matures January 11, 2029 and is secured by substantially all company assets. Armata reported about $4.8 million of unrestricted cash and cash equivalents at March 31, 2026.
A $15 million loan from a unit of Armata's largest shareholder, Innoviva, carries a 14.0% rate, is secured by substantially all of the company's assets and matures in January 2029. Cash stood at $4.3 million on June 30, 2025.
The audit opinion in Armata's 2024 annual report contains a going concern explanatory paragraph. The company also received $4.65 million of additional Department of Defense award funding.
The secured term loan matures on March 12, 2026. Armata also pushed back the maturity of three earlier Innoviva credit agreements to the same date.
Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity and potency, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company describes phages as a potentially safer alternative to broad-spectrum antibiotics that can preserve the normal human microbiome. Its first candidate, inhaled AP-PA02, targets chronic pulmonary infections due to Pseudomonas aeruginosa. AP-PA02 completed a Phase 1b/2a study in cystic fibrosis, supported by a $5.0 million Therapeutics Development Award from the CFF, and a Phase 2 study in non-cystic fibrosis bronchiectasis (NCFB) called Tail wind. The company reports that Tail wind results, announced December 19, 2024, showed a durable reduction of P. aeruginosa in the lung with a favorable safety and tolerability profile. A second candidate, AP-SA02, targets a different bacterial pathogen. The company says it has completed three Phase 2 clinical trials to date. It also describes manufacturing improvements that increase phage titers and purity.
| Product or program | What it is | Stage |
|---|---|---|
| AP-PA02 | Inhaled phage therapy for chronic Pseudomonas aeruginosa lung infections | Phase 2 completed in NCFB |
| AP-SA02 | Phage candidate targeting a second bacterial pathogen | clinical candidate |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$173.8 million | -$18.9 million |
| Cash from operations | -$25.8 million | -$37.6 million |
| Cash and equivalents | $8.7 million | $9.3 million |
Our latest story on this, dated May 1, 2025: "Armata Pharmaceuticals flags going concern paragraph, gets $4.65 million from DoD". The story links the filing or release it is based on. Read the story.
Armata Pharmaceuticals, Inc. trades under the ticker ARMP on AMEX.
Armata Pharmaceuticals, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:TG1N; LS:A2PKLC; LSX:A2PKLC.
The SEC Central Index Key (CIK) for Armata Pharmaceuticals, Inc. is 921114. Its filings are on SEC EDGAR.
37,181,979 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Armata Pharmaceuticals, Inc. under United States.
Our directory classifies Armata Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Armata Pharmaceuticals, Inc. is US04216R1023.
aibio.space lists Armata Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as WA.
Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity and potency, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company describes phages as a potentially safer alternative to broad-spectrum antibiotics that can preserve the normal human microbiome.
AP-PA02: Inhaled phage therapy for chronic Pseudomonas aeruginosa lung infections Stage: Phase 2 completed in NCFB.
AP-SA02: Phage candidate targeting a second bacterial pathogen Stage: clinical candidate.
Armata Pharmaceuticals, Inc. reported a net loss of $173.8 million for the fiscal year ended Dec 31, 2025, and used $25.8 million of cash in operations, per its annual report to the SEC.
$24.0 million in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio